⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INCY News
Incyte Genomics Inc
Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
prnewswire.com
LLY
INCY
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
INCY
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
businesswire.com
INCY
Incyte Announces Additional FDA Approval of Opzelura ® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
businesswire.com
INCY
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
businesswire.com
INCY